VX-371
Phase 2Small molecule
VX-371 is one of 36 small molecule programs targeting Primary Ciliary Dyskinesia. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Onglyza
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Aztreonam Lysine
GileadPreclinical
VX-371
PParion Sciences
Phase 2
Advil
KKenvue Brands
Preclinical
Feosol
AAuerbach Hematology Oncology Associates P C
Preclinical
Amitiza
SSucampo Pharma Americas, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VX-371. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PParion Sciences